Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
A model to estimate spleen volume from palpated spleen length in patients with myelofibrosis.
Journal: Annals of hematology
Published: April 01, 2026
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Journal: Hematological oncology
Published: February 17, 2023
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Rheumatology
Published: April 04, 2022
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Journal: The New England journal of medicine
Published: July 14, 2021
Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19-Associated Cytokine Storm.
Journal: Delaware journal of public health
Published: July 01, 2020
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Journal: Clinical immunology (Orlando, Fla.)
Published: May 15, 2020
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Journal: Journal of hematology & oncology
Published: August 08, 2017
Last Updated: 09/26/2026